Heidelberg Pharma Aktie
| 2,80EUR | 0,02EUR | 0,72% |
WKN DE: A11QVV / ISIN: DE000A11QVV0
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 96 | 110 | 105 | 116 | 120 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,02 | 0,17 | 0,09 | 0,06 | 0,01 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 9 | 88 | 57 | 48 | 28 |
| Summe Anlagevermögen | 13 | 13 | 14 | 13 | 10 |
| Summe Aktiva | 22 | 101 | 70 | 61 | 38 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 15 | 34 | 21 | 30 | 49 |
| Summe Eigenkapital | 7 | 67 | 49 | 31 | -11 |
| Summe Passiva | 22 | 101 | 70 | 61 | 38 |
Adresse
| Gregor-Mendel-Strasse 22, 68526 Ladenburg | |
| Telefon | +49 (6209) 1009-0 |
| Fax | +49 (6209) 1009-19 |
| Internet | http://heidelberg-pharma.com |
Management
|
András Strassz
Chief Medical Officer |
|
Birgit Kudlek
Member-Supervisory Board |
|
Dong Zhou Liu
Chief Executive Officer |
|
Georg F. Baur
Deputy Chairman-Supervisory Board |
|
George Badescu
Chief Business Officer |
|
Jörg Kemkowski
Chief Operating Officer |
|
Karl Benedikt Biesinger
Chairman-Supervisory Board |
|
Klaus Schollmeier
Member-Supervisory Board |
|
Mathias Hothum
Deputy Chairman-Supervisory Board |
|
Sylvia Wimmer
Director-Corporate Communications |
|
Walter Miller
Chief Financial Officer |
|
Yan Xia
Member-Supervisory Board |
|
Yvonne Halbig
Head-Human Resources |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.